MDGL
Price
$314.64
Change
+$6.05 (+1.96%)
Updated
Jul 10 closing price
Capitalization
6.85B
26 days until earnings call
MNKD
Price
$3.81
Change
-$0.01 (-0.26%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
1.16B
26 days until earnings call
Interact to see
Advertisement

MDGL vs MNKD

Header iconMDGL vs MNKD Comparison
Open Charts MDGL vs MNKDBanner chart's image
Madrigal Pharmaceuticals
Price$314.64
Change+$6.05 (+1.96%)
Volume$188.65K
Capitalization6.85B
MannKind
Price$3.81
Change-$0.01 (-0.26%)
Volume$46.04K
Capitalization1.16B
MDGL vs MNKD Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. MNKD commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (MDGL: $314.64 vs. MNKD: $3.80)
Brand notoriety: MDGL and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 62% vs. MNKD: 71%
Market capitalization -- MDGL: $6.85B vs. MNKD: $1.16B
MDGL [@Biotechnology] is valued at $6.85B. MNKD’s [@Biotechnology] market capitalization is $1.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • MNKD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both MDGL and MNKD are a good buy in the short-term.

Price Growth

MDGL (@Biotechnology) experienced а +5.28% price change this week, while MNKD (@Biotechnology) price change was +5.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.85B) has a higher market cap than MNKD($1.16B). MDGL YTD gains are higher at: 1.967 vs. MNKD (-40.902). MNKD has higher annual earnings (EBITDA): 82.6M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. MNKD (182M). MNKD has less debt than MDGL: MNKD (47.2M) vs MDGL (120M). MDGL has higher revenues than MNKD: MDGL (317M) vs MNKD (298M).
MDGLMNKDMDGL / MNKD
Capitalization6.85B1.16B590%
EBITDA-376.15M82.6M-455%
Gain YTD1.967-40.902-5%
P/E RatioN/A38.00-
Revenue317M298M106%
Total Cash843M182M463%
Total Debt120M47.2M254%
FUNDAMENTALS RATINGS
MDGL vs MNKD: Fundamental Ratings
MDGL
MNKD
OUTLOOK RATING
1..100
7251
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
3957
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5588
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (48) in the Biotechnology industry is in the same range as MDGL (64) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is in the same range as MNKD (57) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MNKD’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MNKD (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MNKD’s over the last 12 months.

MDGL's Price Growth Rating (55) in the Pharmaceuticals Other industry is somewhat better than the same rating for MNKD (88) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (99) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLMNKD
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMLEX59.710.24
+0.40%
American Funds American Mutual 529E
NEFOX31.15N/A
N/A
Natixis Oakmark A
VYRDX16.83N/A
N/A
VY® Columbia Small Cap Value II R6
SWLGX127.37N/A
N/A
Schwab ® US Large-Cap Growth Idx
MAVKX14.30N/A
N/A
MoA Small Cap Value Fund